TITLE

CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

AUTHOR(S)
Sandborn, W. J.; Feagan, B. G.; Radford-Smith, G.; Kovacs, A.; Enns, R.; Innes, A.; Patel, J.
PUB. DATE
October 2004
SOURCE
Gut;Oct2004, Vol. 53 Issue 10, p1485
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Targeting tumour necrosis factor α (TNF-α) has demonstrated efficacy in Crohn's disease. Aim: To evaluate CDP571, a humanised antibody to TNF-α, for treating active Crohn's disease. Patients: A total of 396 patients with moderate to severe Crohn's disease. Methods: In a 28 week, randomised, double blind, placebo controlled trial, patients received intravenous CDP571 (10 mg/kg) or placebo every eight weeks to week 24. The primary outcome measure was clinical response (a decrease in the Crohn's disease activity index (CDAI) to ⩾100 points or remission (CDAI score ⩽150 points)) at week 28. A secondary outcome measure was clinical response (using the same definition) at week 2. Results:Clinical response occurred at week 28 in 80/263 (30.4%) CDP571 patients and 31/132 (23.5%) placebo patients (p = 0.102). Clinical response at week 2 occurred in 90/263 (34.2%) CDP571 patients and 28/132 (21.2%) placebo patients (p = 0.011). Post hoc exploratory subgroup analysis of 159 patients with baseline C reactive protein (CRP) ⩾10 mg/l demonstrated significant differences between CDP571 and placebo in clinical response rates at weeks 2 (CDP571, 50/101 (49.5%); placebo, 9/58 (15.5%); p<0.001) and 28 (CDP571, 29/101 (28.7%); placebo, 7/58 (12.1%); p = 0.018). Adverse events occurred at similar frequencies in both treatment groups. Conclusions:CDP571 is modestly effective for short but not long term treatment of unselected patients with moderate to severe Crohn's disease. The clinical relevance of this short term effect is unclear. Post hoc analysis suggests both short and long term efficacy of CDP571 in patients with elevated baseline CRP (⩾10 mg/l). CDP571 is well tolerated.
ACCESSION #
14674396

 

Related Articles

  • Reactivation of Latent Granulomatous Infections by Infliximab. Wallis, Robert S.; Broder, Michael; Wong, John; Lee, Albert; Hoq, Lalima // Clinical Infectious Diseases;8/1/2005 Supplement, Vol. 41, pS194 

    Although infliximab and etanercept share tumor necrosis factor (TNF) as a common therapeutic target, accumulating data indicate that infliximab (an anti-TNF monoclonal antibody) poses a greater risk of reactivation of latent granulomatous infections than does etanercept (a soluble TNF receptor)....

  • Selective cytotoxicity of scFv-TNF fusion protein on the tumor cells. Luo, Dong; Li, Hongshi; Tang, Xiao-Bo // Biotechnology Letters;Mar2002, Vol. 24 Issue 6, p441 

    A fusion protein of single-chain, Fv-tumor necrosis factor α, scFv-TNF, was constructed and expressed in the Pichia pastoris expression system. There was 67-fold less toxicity of the fusion protein when compared with TNF-α alone in cells expressing CA125. Furthermore, scFv-TNF was 10-fold...

  • Tumor necrosis factor-α and muscle wasting: a cellular perspective. Reid, Michael B.; Yi-Ping Li // Respiratory Research;2001, Vol. 2, p1 

    Tumor necrosis factor-α (TNF-α) is a polypeptide cytokine that has been associated with muscle wasting and weakness in inflammatory disease. Despite its potential importance in muscle pathology, the direct effects of TNF-α on skeletal muscle have remained undefined until recently....

  • The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Narayan, Nisha; Lee, In Hye; Borenstein, Ronen; Sun, Junhui; Wong, Renee; Tong, Guang; Fergusson, Maria M.; Liu, Jie; Rovira, Ilsa I.; Cheng, Hwei-Ling; Wang, Guanghui; Gucek, Marjan; Lombard, David; Alt, Fredrick W.; Sack, Michael N.; Murphy, Elizabeth; Cao, Liu; Finkel, Toren // Nature;12/13/2012, Vol. 492 Issue 7428, p199 

    Although initially viewed as unregulated, increasing evidence suggests that cellular necrosis often proceeds through a specific molecular program. In particular, death ligands such as tumour necrosis factor (TNF)-? activate necrosis by stimulating the formation of a complex containing...

  • Tumor Necrosis Factor and Lymphotoxin: Molecular Genetics, Regulation and Physiological Role. Nedospasov, S. A. // Russian Journal of Genetics;Feb2003, Vol. 39 Issue 2, p152 

    The data on the regulation of expression and on the biological role of the tumor necrosis factor and lymphotoxin in the author's laboratory, are briefly reviewed in this paper.

  • Permeability of dialyzer membranes to TNFa-inducing substances derived from water bacteria. Lonnemann, Gerhard; Behme, Tim C.; Lenzner, Benedikt; Floege, Juergen; Schulze, Matthias; Colton, Clark K.; Koch, Karl M.; Shaldon, Stanley // Kidney International;Jul1992, Vol. 42 Issue 1, p61 

    Pro-inflammatory cytokine-inducing substances derived from cultured E. coli have previously been shown to pass across low-flux regenerated cellulosic dialyzer membranes. In the present study, a sterile filtrate of Pseudomonas maltophilia grown from standard bicarbonate dialysis fluid was used to...

  • A novel tumor necrosis factor (TNF) gene present in tandem with theTNF-a gene on the same chromosome in teleosts. Savan, Ram; Kono, Tomoya; Igawa, Daisuke; Sakai, Masahiro // Immunogenetics;Apr2005, Vol. 57 Issue 1/2, p140 

    Tumor necrosis factors (TNFs) are pleiotropic cytokines implicated in inflammation, apoptosis, cell proliferation, and a general stimulation of immune system. Although theTNF/lymphotoxin (LT) locus is present in the MHC region of the chromosome in mammals, no such locus has been described from...

  • Silencing TNFa activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice. Grounds, Miranda D.; Davies, Marilyn; Torrisi, Jo; Shavlakadze, Thea; White, Jason; Hodgetts, Stuart // Cell & Tissue Research;Jun2005, Vol. 320 Issue 3, p509 

    Dramatic clinical success in the treatment of chronic inflammatory diseases has resulted from the use of anti-cytokine therapies including specific blocking antibodies, soluble receptors and traps to silence the actions of inflammatory cytokines such as tumour necrosis factor alpha (TNFa) and...

  • Factor de Necrosis Tumoral-alfa e Interleucina-1 beta en los compartimentos intravascular materno, fetal y retroplacentario en parto a término y pretérmino. Hernandez-Guerrero, Cesar; Vadillo-Ortega, Felipe; Arechavaleta-Velasco, Fabian; Tenorio-Ramos, Javier; Jimenez-Zamudio, Luis; Ahued-Ahued, Jose R.; Beltran-Montoya, Jorge; Neri-Mendez, Carlos // Perinatologia y Reproduccion Humana;jul-sep1999, Vol. 13 Issue 3, p227 

    KEY WORDS: Proinflammatory citokynes, Tumor Necrosis Factor-alpha, Interleukin-1 beta.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics